{"created":"2023-06-20T14:26:08.888314+00:00","id":1473,"links":{},"metadata":{"_buckets":{"deposit":"85b3979f-cb68-48ec-8092-08599e525d15"},"_deposit":{"created_by":14,"id":"1473","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"1473"},"status":"published"},"_oai":{"id":"oai:dmu.repo.nii.ac.jp:00001473","sets":["81:86"]},"author_link":["4072","5808","4065","4073"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-03-25","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"23","bibliographicPageStart":"17","bibliographicVolumeNumber":"44","bibliographic_titles":[{"bibliographic_title":"Dokkyo Journal of Medical Sciences"}]}]},"item_10001_description_34":{"attribute_name":"要旨","attribute_value_mlt":[{"subitem_description":"Introduction：To evaluate the efficacy and safety of once daily phosphodiesterase type 5 inhibitor(PDE5i) tadalafil as an add-on treatment for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia（BPH/LUTS）refractory to an alpha 1-blocker（a1-blocker）. \n\nMaterials and Methods：This study enrolled men aged ＞50 years with BPH/LUTS and erectile dysfunction(ED) that were refractory to ＞3 months of a1-blocker. We defined “refractory” as an international prostate symptoms score (IPSS) of ＞8 and a maximum flow rate (Qmax) ＜15 despite in no space take of an a1-blocker. Patients with contraindications to phosphodiesterase-5 inhibitors；those with symptoms of other diseases that were difficult to differentiate from BPH/LUTS；and those with postvoid residual of ＞100 ml were excluded. Eligible patients received added-on treatment with tadalafil 5 mg/day for 12 weeks. \n\nResults：Tadalafil add-on treatment significantly improved the IPSS parameters in terms of total score（P＜0.001）, subscore for storage（P＝0.001）, subscore for voiding（P＜0.001）, and quality of life（P＝0.002）. The 3-day frequency volume chart showed significant improvements in mean number of daily nocturnal micturations（P＝0.002）, nocturnal polyuria index（P＝0.001）, and hours of undisturbed sleep（P＝0.006）. Five patients dropped out because of an adverse event：two with a headache, two with dizziness and one with dyspepsia. There were no serious adverse events. \n\nConclusion：Tadalafil add-on treatment was effective for patients with BPH/LUTS and ED that were resistant to a1-blockers.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"獨協医学会"}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00629581","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03855023","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_24":{"attribute_name":"著者所属","attribute_value_mlt":[{"subitem_text_value":"Department of Urology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan"},{"subitem_text_value":"Department of Urology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan"},{"subitem_text_value":"Department of Urology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan"},{"subitem_text_value":"Department of Urology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan"}]},"item_10001_text_28":{"attribute_name":"表示順","attribute_value_mlt":[{"subitem_text_value":"４"}]},"item_10001_text_33":{"attribute_name":"記事種別","attribute_value_mlt":[{"subitem_text_value":"Original"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yagi, Hiroshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Arai, Gaku","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Soh, Shigehiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Okada, Hiroshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-09"}],"displaytype":"detail","filename":"DJMS-44-1-4.pdf","filesize":[{"value":"86.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"DJMS-44-1-Yagi2-本文","url":"https://dmu.repo.nii.ac.jp/record/1473/files/DJMS-44-1-4.pdf"},"version_id":"c1bb3320-afa6-4f15-b74e-d25514716e16"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"tadalafil","subitem_subject_scheme":"Other"},{"subitem_subject":"benign prostatic hyperplasia","subitem_subject_scheme":"Other"},{"subitem_subject":"lower urinary tract symptoms","subitem_subject_scheme":"Other"},{"subitem_subject":"refractory to alpha-1 adrenoceptor blockers","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Efficacy of Tadalafil Add-on Treatment for Men with Lower Urinary Tract Symptoms Refractory to Alpha-1 Adrenoceptor Blockers","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy of Tadalafil Add-on Treatment for Men with Lower Urinary Tract Symptoms Refractory to Alpha-1 Adrenoceptor Blockers"}]},"item_type_id":"10001","owner":"14","path":["86"],"publish_date":"2018-07-09","publish_status":"0","recid":"1473","relation_version_is_last":true,"title":["Efficacy of Tadalafil Add-on Treatment for Men with Lower Urinary Tract Symptoms Refractory to Alpha-1 Adrenoceptor Blockers"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-06-20T15:44:35.261450+00:00"}